Personalized mRNA Melanoma Shot Clears a Crucial Phase 3 Hurdle

Personalized mRNA Melanoma Shot Clears a Crucial Phase 3 Hurdle
A personalized mRNA treatment for melanoma has delivered its biggest test yet: a Phase 3 success that could push cancer care closer to therapies designed around each patient’s own tumor.

Moderna and Merck said Wednesday that intismeran, their bespoke mRNA neoantigen therapy, met the trial’s primary goals when used alongside Merck’s Keytruda after surgery for high-risk melanoma. The 1,137-patient study compared the combination with Keytruda alone, with participants randomized two-to-one and treated for roughly a year.

At a planned interim analysis, the companies said the combination extended recurrence-free survival and distant metastasis-free survival—measures of how long patients live without the cancer returning, including at a distant site. They called the findings statistically significant and clinically meaningful, but have not yet released the magnitude of the benefit or detailed results.

The development follows encouraging five-year Phase 2 data, in which the combination was associated with a 49% reduction in the risk of recurrence or death and a 59% reduction in distant metastasis or death. The Phase 3 announcement marks a more consequential milestone: a late-stage test of a therapy built to target as many as 34 mutations unique to an individual patient’s tumor.

The companies frame the approach as neoantigen therapy. Moderna Chief Executive Stéphane Bancel called it “a pivotal moment for the field of cancer research,” arguing that a once-aspirational individualized mRNA cancer treatment is becoming real.

Outside optimism remains tempered by what has not been disclosed. Oxford cancer specialist Lennard Lee described it as the first positive Phase 3 trial for an individualized neoantigen therapy and mRNA-based cancer treatment, while stressing that survival, subgroup and quality-of-life data will determine which patients benefit most and where the treatment fits into routine care.

For now, the companies have a breakthrough claim—and a coming medical meeting where the numbers behind it will face their first full public scrutiny.

Continue reading https://foxvector.com/stories/01a02181-d91f-1798-7089-1009ce6fb39e